TRPHARM Ilac Sanayi Tic AS:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:TRPHARM Ilac Sanayi Tic AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10962
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:トルコ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
TRPHARM Ilac Sanayi Tic AS (TRPharm) is a biopharmaceutical company focused on development and commercialization of novel innovative medicines for the treatment of oncology, neurology, inflammatory and rare diseases. The company conducts research and development programs and provide treatments for a healthy lifestyle for suitable patients, healthcare professional, and health related authorities. TRPharm’s pipeline products include RPH-001, RPH-104, rituximab biosimilar indicated for the treatment of Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Lymphoma (CLL). The company offers a range of monoclonal antibodies, and biosimilars in the therapeutic areas of virology, inflammatory diseases, oncology, and other rare diseases. It has partnerships with other pharmaceutical companies for production and healthcare service techniques. TRPharm is headquartered in Istanbul, Turkey.

TRPHARM Ilac Sanayi Tic AS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
TRPHARM Enters into Distribution Agreement with Kastle Therapeutics 10
TRPharm and Leadiant Biosciences Enter into Distribution Agreement 11
Dr. Reddy’s Labs Enters into Agreement with TR-Pharm 12
TR-Pharm Enters into Distribution Agreement with Sigma-Tau Rare Disease 13
Licensing Agreements 14
TRPharm Enters into Licensing Agreement with Foresee Pharma 14
TR-Pharm Enters into Licensing Agreement with CrystalGenomics 15
TR-Pharm Enters into Licensing Agreement with Toyama Chemical 16
Equity Offering 17
R-Pharm Invests USD136 Million in TR-Pharma 17
TRPHARM Ilac Sanayi Tic AS – Key Competitors 18
TRPHARM Ilac Sanayi Tic AS – Key Employees 19
TRPHARM Ilac Sanayi Tic AS – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Key Facts 2
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TRPHARM Ilac Sanayi Tic AS, Deals By Therapy Area, 2012 to YTD 2018 8
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
TRPHARM Enters into Distribution Agreement with Kastle Therapeutics 10
TRPharm and Leadiant Biosciences Enter into Distribution Agreement 11
Dr. Reddy's Labs Enters into Agreement with TR-Pharm 12
TR-Pharm Enters into Distribution Agreement with Sigma-Tau Rare Disease 13
TRPharm Enters into Licensing Agreement with Foresee Pharma 14
TR-Pharm Enters into Licensing Agreement with CrystalGenomics 15
TR-Pharm Enters into Licensing Agreement with Toyama Chemical 16
R-Pharm Invests USD136 Million in TR-Pharma 17
TRPHARM Ilac Sanayi Tic AS, Key Competitors 18
TRPHARM Ilac Sanayi Tic AS, Key Employees 19
TRPHARM Ilac Sanayi Tic AS, Other Locations 20

List of Figures
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TRPHARM Ilac Sanayi Tic AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[TRPHARM Ilac Sanayi Tic AS:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AnaMar AB:医療機器:M&Aディール及び事業提携情報
    Summary AnaMar AB (AnaMar), a subsidiary of Koncentra Holding AB, is a drug discovery company that discovers, develops and commercializes therapeutic strategies to treat debilitating inflammation, fibrosis and pain. The company develops drug candidates from several chemical classes on the receptors …
  • Noevir Holdings Co Ltd (4928):企業の財務・戦略的SWOT分析
    Noevir Holdings Co Ltd (4928) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Waterstone Financial Inc (WSBF):企業の財務・戦略的SWOT分析
    Waterstone Financial Inc (WSBF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • ARCA biopharma Inc (ABIO):企業の財務・戦略的SWOT分析
    Summary ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment …
  • Gedeon Richter Plc:企業の戦略・SWOT・財務情報
    Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report Summary Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • ERG Power Generation SpA:企業の戦略的SWOT分析
    ERG Power Generation SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Atea ASA (ATEA):企業の財務・戦略的SWOT分析
    Atea ASA (ATEA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • The Real Good Food Company plc:企業の戦略・SWOT・財務分析
    The Real Good Food Company plc - Strategy, SWOT and Corporate Finance Report Summary The Real Good Food Company plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Fronius International GmbH:企業の戦略的SWOT分析
    Fronius International GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Australia and New Zealand Banking Group Ltd:企業の戦略・SWOT・財務情報
    Australia and New Zealand Banking Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Australia and New Zealand Banking Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Nippon Shinyaku Co Ltd (4516):企業の財務・戦略的SWOT分析
    Nippon Shinyaku Co Ltd (4516) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • TUV Rheinland AG:企業の戦略的SWOT分析
    TUV Rheinland AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Connecticut Children’s Medical Center-製薬・医療分野:企業M&A・提携分析
    Summary Connecticut Children's Medical Center (CCMC) is a children’s hospital that offers primary care and residency and fellowship programs in pediatrics. The hospital offers services such as allergy and immunology, anesthesiology, asthma center, audiology, ccmc school, cancer and blood disorders, …
  • OraSure Technologies Inc (OSUR):医療機器:M&Aディール及び事業提携情報
    Summary OraSure Technologies Inc (OraSure) is a manufacturer and distributor of oral fluid specimen collection devices, diagnostic products and other medical devices. Its product portfolio encompasses infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; Ebola v …
  • Chaucer Holdings Limited:企業の戦略・SWOT・財務情報
    Chaucer Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Chaucer Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Protonex Technology Corporation:電力:M&Aディール及び事業提携情報
    Summary Protonex Technology Corporation (Protonex) is a fuel cell company, which carries out research, development and production of a wide range of power solutions. It principally offers advanced fuel cell power solutions for portable, remote and mobile applications. The company produces these prod …
  • IJM Corporation Berhad:企業の戦略・SWOT・財務情報
    IJM Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary IJM Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Owens Corning (OC):企業の財務・戦略的SWOT分析
    Owens Corning (OC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Sumitomo Chemical Co., Ltd.:企業の戦略・SWOT・財務情報
    Sumitomo Chemical Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Chemical Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Viridian Group Investments Ltd:企業の戦略的SWOT分析
    Viridian Group Investments Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆